Production areas feature clean room spaces. The new facility more than quadruples the company’s capacity to manufacture oral solid-dose pharmaceutical products in the U.S. to well over 1 billion doses annually. The facility enables Mayne Pharma to offer clients a comprehensive “concept to commercialization” solution under one FDA site registration. Special consideration was provided to reduce the risk of cross-contamination within the facility by designing specific flows of personnel, materials, and equipment.